-- 週四,瑞士股市指數反彈走高,收盤上漲0.80%,在勞動節假期前夕,投資人將目光轉向歐洲最新的經濟數據和關鍵貨幣政策決定。 瑞士KOF經濟晴雨表4月升至97.9點,高於上月修正後的95.6點。 KOF瑞士經濟研究所表示:「繼上月大幅下跌後,該指數仍低於其中期平均水平。儘管本月有所回升,但瑞士經濟前景依然疲軟。在經濟晴雨表包含的各項指標中,製造業、其他服務業和私人消費指標均顯示出尤為積極的發展態勢。” 其他方面及監理方面,歐洲央行如預期維持三大基準利率不變。英國央行貨幣政策委員會以8比1的投票結果決定維持利率不變,英國央行也維持3.75%的銀行利率不變。兩家央行都警告稱,中東衝突持續推高能源價格,對通膨構成上行風險。 荷蘭國際集團(ING)表示:「總而言之,今天歐洲央行會議的主要結論或許可以概括為立場再次鷹派化,其觀望態度明顯轉向加息。目前仍很難看出歐洲央行是否真的願意以加劇經濟衰退為代價來應對外生供應衝擊。然而,無論加息是像徵性的還是政策失誤,6月會議上加息的可能性都明顯增加。 企業方面,歐瑞康(OC Oerlikon,股票代號:OERL.SW)第一季訂單量與銷售額分別較去年同期成長17.9%及5.3%,達4.55億瑞士法郎及3.78億瑞士法郎(皆以固定匯率計算)。這家瑞士表面技術和先進材料公司的股價在收盤時上漲了4.43%。 瑞士製藥商諾華(NOVN.SW)的股價也上漲了2.26%,此前該公司宣布計劃在美國北卡羅來納州開設一家新工廠,生產用於固體製劑片劑、膠囊和RNA療法的活性藥物成分。該工廠是該公司在美國投資230億美元以提升產能的更廣泛計畫的一部分。 瑞士證券交易所(SIX Swiss Exchange)將於5月4日重新開市。
Related Articles
Sector Update: Financial
Financial stocks were higher late Thursday afternoon, with the NYSE Financial Index rising 1.3% and the State Street Financial Select Sector SPDR ETF (XLF) up 0.5%.The Philadelphia Housing Index climbed 1.6%, and the State Street Real Estate Select Sector SPDR ETF (XLRE) added 1.5%.Bitcoin (BTC-USD) rose 0.9% to $76,409, and the yield for 10-year US Treasuries decreased 2.8 basis points to 4.39%.In corporate news, AvalonBay Communities (AVB) and Equity Residential (EQR) have held discussions over a potential merger, which would be one of the biggest real estate deals ever, Bloomberg reported. AvalonBay shares were down 1.1%, and Equity Residential was fractionally lower.
Market Chatter: Zuckerberg, Cook Not Exploring Seattle Seahawks Bid
Meta Platforms (META) CEO Mark Zuckerberg and Apple (AAPL) CEO Tim Cook are not pursuing a bid for the National Football League's Seattle Seahawks, Bloomberg reported on Thursday, citing company and industry sources.A Meta spokesperson said Zuckerberg is not making any investment or bid for the team, while a person familiar with Cook's plans denied his involvement, the report said.Meta and Apple did not immediately respond to requests for comment from.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)Price: $616.43, Change: $-52.69, Percent Change: -7.87%
Axsome Therapeutics Says FDA Approves Auvelity for Alzheimer's Disease Agitation
Axsome Therapeutics (AXSM) said Thursday the US Food and Drug Administration approved Auvelity for the treatment of agitation associated with Alzheimer's disease dementia.The approval was supported by two phase 3 clinical trials that showed the drug significantly improved agitation symptoms and resulted in a longer time to relapse compared with placebo.The medication acts on N-methyl-D-aspartate and sigma-1 receptors in the brain and is also approved for adults with major depressive disorder, the company added.Shares of Axsome were up more than 12% in Thursday trading.Price: $206.45, Change: $+22.50, Percent Change: +12.23%